ArticleBMC pregnancy and childbirth2026
Prenatal characteristics and clinical outcomes in 82 cases with agenesis of corpus callosum: single tertiary center experience.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAgenesis of the corpus callosum (ACC) is one of the most common structural brain malformations, with a highly variable prognosis. The aim of this study was to investigate all cases of ACC managed at our clinic and to provide a comprehensive assessment of its prenatal features, associated conditions, and postnatal outcomes. MATERIALS AND
methodsWe conducted a retrospective cohort study including all prenatally diagnosed cases of ACC in our maternal-fetal medicine unit between October 2020 and November 2024. Maternal characteristics, gestational age at diagnosis, associated anomalies, genetic testing results, and perinatal outcomes were recorded. Postnatal neurodevelopmental outcomes were assessed using the Denver II test, with a follow-up duration ranging from 6 to 40 months.
resultsA total of 82 fetuses with ACC were collected. Of these, 59.8% (n = 49) had complete and 40.2% (n = 33) had partial ACC. 43.9% (n = 36) of cases were isolated and associated anomalies were detected in 56.1% (n = 46). 37.8% (n = 31) of cases opted for termination of pregnancy, whereas 19.5% (n = 16) resulted in postnatal death, and 42.7% (n = 35) survived. No significant difference was observed between partial and complete isolated ACC cases in terms of postnatal neurodevelopmental outcomes. Genetic abnormalities were identified in 31.1% (19/61) of patients who underwent genetic testing.
conclusionsIn cases of ACC, the most important prognostic factors are the presence of additional anomalies and genetic conditions. Genetic testing, including whole exome sequencing when karyotype and chromosomal microarray results are negative, is strongly recommended, even in isolated cases, to support counseling. In isolated ACC, neurodevelopmental outcomes were favorable in 85.2% (23/27) of patients, regardless of whether ACC was partial or complete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.